Thomas Marron, MD, PhD

Marron spoke about the value that neoantigen vaccines can provide by studying T-cell responses and the characteristics of lymphoid response to antigens.

Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.

Marron detailed the research process for a phase 1 trial of PGV-001 presented virtually at the American Association for Cancer Research Annual Meeting 2021.

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.